The ATM facility provides Kura with flexible, opportunistic capital access given its strong cash position and recent commercial momentum. Monitor actual ATM usage in future filings; the company may draw down slowly to fund KOMZIFTI commercialization and ziftomenib/darlifarnib development without urgency, given existing $492M cash and $300M debt facility.
Drugs in focus
KURA drug pipeline →darlifarnib
● Neutral Named in this S-3ASR- Impact
- Phase
- Phase 1
- Time to market
- Likely 4-6+ years if successful; still in Phase 1 with registrational Phase 3 planned for 2028 at the earliest
- Next catalyst
- None dated
What to watchInvestors should watch the KCRS 2026 oral presentation on July 24 and the virtual investor call on July 27 for updated long-term Phase 1a durability data in ccRCC. The program is too early for binary positioning, the real value inflection points (Phase 1b randomization data, Phase 3 start in 2028, and the daraxonrasib combo entering the clinic in early 2027) are 12+ months away. KURA is a multi-asset company with an approved product, so darlifarnib is one of several value drivers.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 11 $7.73entry
- T+1 · 5d ago −3.88%α −3.53% · $7.43
- T+3 · todayOpen
- T+5 · tomorrow Pending
- T+20 · in 23d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Kura Oncology filed an automatic shelf registration statement (S-3ASR) as a well-known seasoned issuer, including a base prospectus for an indeterminate amount of common stock, preferred stock, debt securities, and warrants, and a sales agreement prospectus for up to $150 million in at-the-market (ATM) common stock offerings through Leerink Partners and Cantor Fitzgerald. The filing follows strong Q3 2026 results with KOMZIFTI net product revenue of $13.9 million (up 53% sequentially) and a cash position of $492.1 million, plus up to $300 million in additional financing capacity from Oberland Capital. The ATM facility provides flexible capital access to support commercialization and pipeline development, with potential dilution of up to 21.6% of shares outstanding at the current price.
Key Facts
- S-3ASR filed as a well-known seasoned issuer with no limit on aggregate securities offered
- Includes a sales agreement prospectus for up to $150 million in ATM common stock sales through Leerink Partners and Cantor Fitzgerald
- As of September 30, 2026, 91,872,597 shares outstanding; at $7.57/share, $150M represents ~19.8M shares or 21.6% dilution
- Q3 2026 KOMZIFTI net product revenue of $13.9 million, up 53% sequentially
- Cash, cash equivalents and short-term investments of $492.1 million as of September 30, 2026
- Up to $300 million additional financing capacity from Oberland Capital ($275M debt, $25M equity)
- Proceeds intended for commercialization of KOMZIFTI, pipeline advancement, and general corporate purposes
- Stock price $7.57 on November 9, 2026; market cap $647 million
Financial Impact
Up to $150 million in potential ATM equity issuance, representing up to 21.6% dilution at current price; company has $492.1M cash plus $300M Oberland facility
Risk Factors
- Potential dilution of up to 21.6% if full $150M ATM is utilized at current price
- ATM sales at prices below current levels would increase dilution
- Company has no minimum offering amount, so actual usage is uncertain
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 2 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3ASR Filing (Primary) | 0001193125-26-455759 |
| Document: d18057dex48.htm | 0001193125-26-455759 |
Track record
29 reports on KURA
6 of 9 bullish or bearish reports moved the stock their way by T+60. Best: +52.28% at T+60 after the Jun 3, 2026 report. 10 of 14 went positive at some point.
Filters
- Nov 16, 2026today Insider Buy Bullish 5/10 Entry $7.15 Now $7.09 −0.84% settles Feb 16
- Nov 16, 2026today 144 Neutral 3/10 Entry $7.15 Now $7.09 −0.84% settles Feb 16
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $7.15 Now $7.09 −0.84% settles Feb 16
- Nov 10, 20266d ago S-3ASR Neutral 4/10 Viewing Entry $7.73 Now $7.09 −8.28% settles Feb 9
- Nov 10, 20266d ago Press Release Neutral 5/10 Entry $7.73 Now $7.09 −8.28% settles Feb 9
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $7.61 Now $7.09 −6.83% settles Feb 2
- Sep 29, 20266w ago Insider Cluster Bearish 5/10 Entry $10.71 Now $7.09 +33.80% settles Dec 24
- Sep 29, 20266w ago Press Release Bullish 6/10 Entry $10.81 Now $7.09 −34.38% settles Dec 23
- Sep 9, 20269w ago 8-K Bullish 6/10 Entry $12.09 Now $7.09 −41.36% settles Dec 3
- Sep 8, 20269w ago 8-K Neutral 2/10 Entry $12.52 Now $7.09 −43.37% settles Dec 2
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers